← Leaderboards
Sheldon Robert Morris
University Of Southern California
$1,511,311
Attributed
$4,262,172
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $782.9K · FY2013–24$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,262,172 · 2
By mechanism
U01$3,718,650 · 1
R21$543,522 · 1
Top collaborators
- Tatiana Kisseleva5 shared
- Rohit Loomba5 shared
- Joel E Milam3 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Tatiana Kisseleva$14,632,761
- Lynn C Miller$7,983,377
- Hooman Allayee$13,512,935
- Bangyan Stiles$6,009,558
- Norah A. Terrault$8,729,722
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingScheduleSamplingPharmaceutical PreparationsEnrollmentPreventParticipantRegimenAlcohol Abuse TherapyAlcohol Use DisorderAdultAffectAntibodiesAntibody TherapyClinical Trial AnalysisClinicAlcoholic SteatohepatitisChronic Liver DiseaseClinical DevelopmentCellsAlcoholsCirrhosisBiologicalBlocking Antibodies
Grant awards (8)
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$711,945
U01 · FY2024 · AA
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$742,984
U01 · FY2023 · AA
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$699,515
U01 · FY2022 · AA
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$781,354
U01 · FY2021 · AA
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$782,852
U01 · FY2020 · AA
Risk compensation and pre-exposure prophylaxis use to prevent HIV infection--supplement$82,500
R21 · FY2015 · MH
Risk compensation and pre-exposure prophylaxis use to prevent HIV infection$283,461
R21 · FY2014 · MH
Risk compensation and pre-exposure prophylaxis use to prevent HIV infection$177,561
R21 · FY2013 · MH